Sensorimotor Cortex Excitability in Shoulder Impingement Syndrome

March 22, 2023 updated by: Yin-Liang Lin, National Yang Ming University

Sensorimotor Cortex Excitability in Shoulder Impingement Syndrome and the Sensorimotor Excitability and Control in Acute/Subacute Stage Related to Development of Chronicity

Shoulder pain is a common musculoskeletal system complaint, accounting for 7-34% of patients in the clinic. The most common shoulder problem is subacromial impingement syndrome (SIS). Up to 45% of individuals with SIS may have unsuccessful treatment and still complain of symptoms after 2 years. This chronicity of pain may not be fully explained by structural injuries or damage, but may be related to sensorimotor changes. Decreased corticospinal excitability and increase inhibition have been found in individuals with SIS. These central motor changes may link to alteration in pain and nociception processing and the somatosensory system, which has been found in individuals with low back pain. Hyperalgesia has been found over both affected and unaffected shoulders in patients with SIS, indicating central and peripheral sensitization. However, no study has investigated whether there are changes in the central somatosensory system. Therefore, the objectives of this proposal are (1) to investigate the corticomotor and somatosensory system in patients with SIS (2) to investigate the relationship between the corticomotor and somatosensory alterations in patients with SIS. Subjects with chronic SIS and healthy subjects were recruited, with 32 people in each group. Electroencephalography (EEG) will be used to collect somatosensory activity, including somatosensory evoked potentials, spectral analysis of EEG oscillations and event-related spectral perturbation (ERSP) of the shoulder movement. Electromyography will be used to record muscle activity. Transcranial magnetic stimulation will be used to test corticomotor excitability, including active motor threshold, motor evoked potentials, cortical silent period, and intracortical inhibition and facilitation. The pressure pain threshold will be collected by a pressure algometer on the muscles of bilateral arms and legs. Pain intensity will be assessed with the Numeric Rating Scale. Shoulder function will be evaluated with the Disability of Arm, Shoulder and Hand questionnaire. Depression will be evaluated with Center for Epidemiologic Studies Depression Scale (CES-D).

Study Overview

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Taipei, Taiwan, 112
        • Recruiting
        • National Yang Ming Chiao Tung University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with chronic impingement syndrome, acute/subacute impingement syndrome and the matched healthy control subjects.

Description

Inclusion Criteria (chronic impingement syndrome group):

  1. individuals have shoulder pain localized at the anterior or lateral aspect of shoulder more than six months
  2. are aged 20 to 65 years old
  3. shoulder impingement syndrome, which is confirmed by having at least three of the following: (a) positive Neer's test, (b) positive Hawkins-Kennedy test, (c) positive empty can test, (d) positive resisted external rotation test, and (e) presenting painful arc during arm elevation

Inclusion Criteria (acute/subacute impingement syndrome group):

  1. individuals have shoulder pain localized at the anterior or lateral aspect of shoulder less than six months
  2. are aged 20 to 65 years old
  3. shoulder impingement syndrome, which is confirmed by having at least three of the following: (a) positive Neer's test, (b) positive Hawkins-Kennedy test, (c) positive empty can test, (d) positive resisted external rotation test, and (e) presenting painful arc during arm elevation

Inclusion Criteria (health control group)

  1. individuals without any shoulder and neck problems
  2. sex, age, and hand dominance match to impingement group

Exclusion Criteria:

  1. have a history of dislocation, fracture, adhesive capsulities, or surgery of upper extremity
  2. arm elevation angle less than 150 degrees
  3. a history of direct contact injury to the neck or upper extremities within the past 12 months
  4. brain injury and neurological impairment
  5. inflammatory cause of the pain (e.g., rheumatoid arthritis)
  6. neck pain
  7. psychosis and symptom of headache or dizziness
  8. allergy to plaster
  9. contraindications to the use of TMS, assessed with a safety screening questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
chronic shoulder impingement syndrome
Subjects with shoulder impingement more than 6 months will be included to assess pain threshold, neurophysiological measurements of scapular muscles.
No intervention
control group
Healthy controls without any shoulder and neck problems will be included to compare the differences in pain threshold, neurophysiological measurements of scapular muscles, scapular kinematics and muscle activation between healthy subjects and subjects with chronic or acute shoulder impingement syndrome.
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Corticomotor excitability measures - Active motor threshold
Time Frame: Immediately during the experiment
Active motor threshold (AMT) will be described with the percentage (%) of maximum stimulator output (MSO).
Immediately during the experiment
Corticomotor excitability measures - Motor evoked potential
Time Frame: Immediately during the experiment
Motor evoked potential (MEP) will be described with millivolt (mV).
Immediately during the experiment
Corticomotor excitability measures - Cortical silent period
Time Frame: Immediately during the experiment
Cortical silent period (CSP) will be measured with millisecond (ms)
Immediately during the experiment
Corticomotor excitability measures - Short interval cortical inhibition
Time Frame: Immediately during the experiment
Short interval cortical inhibition (SICI) will be defined as percentage (%) of conditioning responses vs testing responses while the inter-stimulus interval is below 5 ms
Immediately during the experiment
Corticomotor excitability measures - Short interval cortical facilitation
Time Frame: Immediately during the experiment
Short interval cortical facilitation (SICF) will be defined as percentage (%) of conditioning responses vs testing responses while the inter-stimulus interval is above 5 ms
Immediately during the experiment
Corticomotor excitability measures - Long-interval intracortical inhibition
Time Frame: Immediately during the experiment
Long-interval intracortical inhibition (LICI) will be defined as percentage (%) of conditioning responses vs testing responses while the inter-stimulus interval is below 5 ms
Immediately during the experiment
Corticomotor excitability - Area of cortical mapping
Time Frame: Immediately during the experiment
Area of cortical mapping will be described with square millimeter (mm2)
Immediately during the experiment
Corticomotor excitability - Volume of cortical mapping
Time Frame: Immediately during the experiment
Volume of cortical mapping will be calculated with multiplying summation of motor evoke potentials on the map (mV) by the area of the map (mm2) with the unit of mV*mm2
Immediately during the experiment
Corticomotor excitability - Center of gravity of cortical mapping
Time Frame: Immediately during the experiment
Center of gravity of cortical mapping will be described in a x-y coordinate system (mm).
Immediately during the experiment
Resting brain activity - resting EEG with eye open/closed
Time Frame: Immediately during the experiment
EEG signals will be processed with power spectrum density analysis to calculate frequency power at Theta (3-8 Hz), alpha (8-13 Hz), beta (13-30 Hz) bands, and Gamma (30 Hz above).
Immediately during the experiment
Somatosensory cortical activity - Somatosensory evoked potentials
Time Frame: Immediately during the experiment
Somatosensory evoked potentials (SEP) will be described with microvolt (µV) and millisecond (ms).
Immediately during the experiment
Event-related synchronization or desynchronization - Movement evoked pain potentials
Time Frame: Immediately during the experiment
Movement evoked pain potentials will be processed with power spectrum density analysis to calculate frequency power at Theta (3-8 Hz), alpha (8-13 Hz), beta (13-30 Hz) bands, and Gamma (30 Hz above) while raising hand.
Immediately during the experiment
Muscle activation during arm elevation
Time Frame: Immediately during the experiment
The root mean square of electromyography (EMG) data of the anterior deltoid and infraspinatus will be normalized by the maximum voluntary contraction amplitude (percentage of maximal voluntary contraction, %) and calculated in two segments, including arm elevating and arm lowering.
Immediately during the experiment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Shoulder pain and function-Taiwan version of the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire
Time Frame: Immediately during the experiment
Subjects will be asked 30 items related to shoulder functional movement. The overall score ranges from 0 (no disability) to 100 (most severe disability).
Immediately during the experiment
Depression- Taiwan version of the Center for Epidemiologic Studies Depression Scale (CES-D)
Time Frame: Immediately during the experiment
Subjects will be asked 20 items to rate how often over the past week they experienced symptoms associated with depression. Response options range from 0 to 3 for each item. Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
Immediately during the experiment
Pressure pain thresholds
Time Frame: Immediately during the experiment
Pressure pain threshold of bilateral upper trapezius, levator scapulae, infraspinatus, pectoralis major, biceps brachii, middle deltoid and tibialis anterior will each be averaged and will be described with kg/cm2.
Immediately during the experiment
Electrical sensory threshold
Time Frame: Immediately during the experiment
Electrical sensory threshold is the minimal intensity of stimulation required to produce the first perception of sensory and will be described with millivolts (mV).
Immediately during the experiment
Electrical pain threshold
Time Frame: Immediately during the experiment
Electrical pain threshold is the minimal intensity of stimulation required to produce the first perception of pain and will be described with millivolts (mV).
Immediately during the experiment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yin-Liang Lin, PhD, National Yang Ming Chaio Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2022

Primary Completion (Anticipated)

July 31, 2024

Study Completion (Anticipated)

August 31, 2024

Study Registration Dates

First Submitted

November 16, 2022

First Submitted That Met QC Criteria

November 16, 2022

First Posted (Actual)

November 28, 2022

Study Record Updates

Last Update Posted (Actual)

March 23, 2023

Last Update Submitted That Met QC Criteria

March 22, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on No intervention

3
Subscribe